Philip Jones,
Head of Drug Discovery, Institute for Applied Cancer Science. MD Anderson Cancer Center
Philip Jones is the Executive Director and Head of Drug Discovery Institute for Applied Cancer Science at MD Anderson Cancer Center. He has more than fifteen years of drug discovery research experience from Merck Research Laboratories at three locations worldwide. During his career, Jones has led several of Merck’s oncology drug discovery programs, overseeing cross-functional project teams that have successfully delivered novel candidates into ongoing clinical trials. These include Tesaro’s PARP inhibitor niraparib currently completing phase 3 studies, smoothened antagonist and histone deacetylase (HDAC) programs, as well as several undisclosed targets. Jones also was involved in the successful development of Raltegravir, the first-in-class HIV integrase inhibitor.
Jones received his Ph.D. in organic chemistry from the University of Nottingham, UK, and completed his post-doctoral research at Philipps-Universität Marburg, Germany.
|
|
|
